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Abstract
Background: Reactive astrogliosis is a ubiquitous but poorly understood hallmark of central nervous system
pathologies such as trauma and neurodegenerative diseases. In vitro and in vivo studies have identified
proinflammatory cytokines and chemokines as mediators of astrogliosis during injury and disease; however, the
molecular mechanism remains unclear. In this study, we identify astrocyte elevated gene-1 (AEG-1), a human
immunodeficiency virus 1 or tumor necrosis factor α-inducible oncogene, as a novel modulator of reactive
astrogliosis. AEG-1 has engendered tremendous interest in the field of cancer research as a therapeutic target for
aggressive tumors. However, little is known of its role in astrocytes and astrocyte-mediated diseases. Based on its
oncogenic role in several cancers, here we investigate the AEG-1-mediated regulation of astrocyte migration and
proliferation during reactive astrogliosis.
Methods: An in vivo brain injury mouse model was utilized to show AEG-1 induction following reactive astrogliosis.
In vitro wound healing and cell migration assays following AEG-1 knockdown were performed to analyze the role
of AEG-1 in astrocyte migration. AEG-1-mediated regulation of astrocyte proliferation was assayed by quantifying
the levels of cell proliferation markers, Ki67 and proliferation cell nuclear antigen, using immunocytochemistry.
Confocal microscopy was used to evaluate nucleolar localization of AEG-1 in cultured astrocytes following injury.
Results: The in vivo mouse model for brain injury showed reactive astrocytes with increased glial fibrillary acidic
protein and AEG-1 colocalization at the wound site. AEG-1 knockdown in cultured human astrocytes significantly
reduced astrocyte migration into the wound site and cell proliferation. Confocal analysis showed colocalization of
AEG-1 to the nucleolus of injured cultured human astrocytes.
Conclusions: The present findings report for the first time the novel role of AEG-1 in mediating reactive astrogliosis
and in regulating astrocyte responses to injury. We also report the nucleolar localization of AEG-1 in human
astrocytes in response to injury. Future studies may be directed towards elucidating the molecular mechanism of
AEG-1 action in astrocytes during reactive astrogliosis.
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Background
Astrocytes, as the most abundant cell type in the brain,
respond to all forms of central nervous system (CNS)
pathologies, from infection, injury and ischemia to neu-
rodegenerative diseases, by a process commonly referred
to as reactive astrogliosis. During this process, astrocytes
undergo spectrum of changes in their molecular expres-
sion patterns and morphology, leading to both beneficial
and detrimental effects on surrounding neural and non-
neural cells. Despite the ubiquitous presence of reactive
astrocytes at all sites of CNS pathologies, the molecular
mechanisms, functions and effects of reactive astrocytes
are surprisingly poorly understood and their roles in
specific disease processes are largely unclear. Astrocyte
elevated gene-1 (AEG-1), a novel human immunodefi-
ciency virus (HIV)-1 and tumor necrosis factor α
(TNFα)-inducible transcript, was identified in primary
human fetal astrocytes in response to HIV-1 or TNFα
treatment [1]. Subsequent to its identification, several
studies have recognized AEG-1 as an oncogene, whose
expression is elevated in many metastatic malignancies
and is thereby implicated in cancer initiation, metastatic
progression and chemotherapeutic resistance [2-6].
Although much is known about the role of this evolu-
tionarily conserved gene in cancer [7], the role of AEG-1
in normal non-cancerous cells, such as astrocytes, has
not yet been thoroughly investigated. In this report, we
initiate studies to assess the role of AEG-1 in human
astrocytes for mediating injury responses and further
discuss their implications for HIV-1 CNS infection.
AEG-1 mRNA codes for a single pass transmembrane
protein, with predicted molecular weight of 64 kDa,
identified as a metastasis adhesion protein (metadherin)
that enhances migratory capacities of cancer cells [8].
Despite the evolutionary conservativeness, the three-
dimensional structure and functional motifs in the AEG-
1 protein are still unresolved; however, several studies
have reported multiple post-translational modifications,
which might be responsible for the detection of this
protein in varied intracellular compartments [9]. In the
context of cancer, a transcriptional coactivator role has
been attributed to AEG-1 [10] and multiple AEG-1-
interacting proteins have been identified [10-13]. Subse-
quently, AEG-1 has been shown to localize to the
cytoplasm, endoplasmic reticulum, nucleus and nu-
cleolus in cancer cells [9]; however, its role in the diffe-
rent intracellular organelles, often considered a key
determinant for its function, remain to be investigated,
especially in normal non-cancerous cells. The initial
discovery of AEG-1 in astrocytes following HIV-1 or
TNFα treatment [1] implies its role in inflammatory
responses of astrocytes. One of the major cellular mani-
festations of astrocyte inflammatory responses is reactive
astrogliosis, in which activated astrocytes undergo rapid
proliferation, enhanced migration towards the site of in-
flammation and attempt to mitigate collateral damage by
isolating the damaged area [14-16].
As a hallmark of CNS pathologies, reactive astrogliosis
is frequently associated with CNS insults such as infec-
tion, trauma, ischemia, neurodegeneration and post-
neurosurgical healing, commonly associated with the
management of brain tumors [17-19]. Gliosis is accom-
panied with increased expression of inflammatory cyto-
kines and growth factors by surrounding astrocytes,
which initiates a paracrine loop of signaling, potentiating
proliferation, recolonization and migration of surviving
cancer cells from the primary site of origin to secondary
sites [20-22]. Since 70% to 95% of tumors recur from the
tissues proximate to resection margins, reactive astro-
gliosis appears to create a favorable environment for
cancer recurrence [23-26]. Thus, reactive astrogliosis is a
significant phenomenon determining the rate of complete
tumor clearance following conventional therapeutic inter-
ventions. Interestingly, the physiological changes in
astrocyte behavior, function and outcome during hyper-
proliferative disorders, such as astrogliomas, which ex-
press very high levels of AEG-1, resemble those that occur
during reactive astrogliosis [27], suggesting a common de-
nominator. In spite of AEG-1 expression being minimal in
non-cancerous adult cells, AEG-1 is highly expressed dur-
ing the early mouse embryo developmental period from
E8.5 to E9.5, suggesting a role in neurogenesis [28]. As
AEG-1 has been shown to enhance cancer cell migration
and proliferation as an adhesion protein and by inducing
survival signals, it is likely to modulate astrocyte injury
responses and ultimately affect the gliosis process and
neurogenesis post-glial scar formation. Therefore, taking
into account the pleotropic effects of AEG-1 in cancers,
here we investigate the role of AEG-1 in orchestrating
astrocytic responses to injury.
In this study, we show that AEG-1 is required for mi-
gration and proliferation of injured astrocytes to the site
of injury. Results from this study, for the first time, iden-
tify AEG-1 as a novel mediator of reactive astrogliosis,
implicating its role in neuroinflammation, consistent
with its original identification in neuroinflammatory dis-
ease, HIV-1 CNS infection.
Methods
Non-obese diabetic-severe combined immunodeficiency
mouse model of brain injury
Male, 4-week-old NOD-C.B-17 SCID mice were pur-
chased from the Jackson Laboratory (Bar Harbor, ME,
USA). Animals were maintained in sterile microisolator
cages under pathogen-free conditions in accordance
with the ethical guidelines for laboratory animals as set
forth by the National Institutes of Health. All animal
manipulations, including stereotactic injections, were
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performed in a laminar flow hood. Briefly, the animal
was anesthetized and placed in a stereotaxic apparatus
(Stoetling, Wood Dale, IL, USA) and intracranially
injected as previously described [29]. Briefly, the animal’s
head was secured with ear bars and mouthpiece. A 10 μl
syringe injector was used to deliver a total of 5 μl of
phosphate buffered saline (PBS) into the left hemisphere
of the animal and the contralateral right hemisphere was
used as control. Mice were killed 4 days post injection.
Each brain was formalin fixed, embedded in paraffin and
cut into 5 μm sections. The sections through the needle
tract were identified by staining every eighth section
with glial fibrillary acidic protein (GFAP) and 4',6-diami-
dino-2-phenylindole (DAPI, Life Technologies, Carlsbad,
CA, USA). Adjacent sections surrounding the needle tract
were stained by immunohistochemistry with primary anti-
bodies specific to AEG-1 (1:100, rabbit monoclonal, Life
Technologies) and GFAP (1:200, chicken polyclonal,
Covance Inc., Emeryville, CA, USA) and Alexa FluorW
secondary antibodies, anti-rabbit (488 nm, green) and
anti-chicken (594 nm, red) (1:100, Life Technologies),
respectively. DAPI (1:800) was used to visualize the nuclei.
Fluorescent images were visualized with an ECLIPSE Ti-4
using the NLS-Elements BR. 3.0 software (Nikon, Melville,
NY, USA).
Isolation and cultivation of primary human astrocytes
Human astrocytes were isolated from elective abortus
specimens procured in full compliance with the ethical
guidelines of the National Institute of Health, University
of Washington and North Texas Health Science Center,
as previously described [30]. Briefly, brain tissues were
dissected and mechanically dissociated. Cell suspensions
were centrifuged, suspended in media and plated at a
density of 20 × 106 cells/150 cm2 flasks. The adherent
astrocytes were treated with trypsin and cultured under
similar conditions to enhance the purity of replicating
astroglial cells. The astrocyte preparations were routinely
>99% pure as measured by immunocytochemistry stain-
ing for GFAP and microglial marker, CD68, to determine
microglial content and possible contribution of microglia
in inflammatory responses.
RNA extraction and gene expression analysis
RNA was isolated (as described in [31]) from astrocytes
treated as described in subsequent sections and gene
expression was assayed by real-time polymerase chain
reaction (PCR). TaqMan 5’ nuclease real-time PCR was
performed using a StepOnePlus sequence detection
system (Life Technologies). Commercially available
TaqManW Gene Expression Assays were used to measure
AEG-1 (Life Technologies, cat. no. 4331182) and glyce-
raldehyde 3-phosphate dehydrogenase (GAPDH) mRNA
levels (Life Technologies, cat. no. 4310884E). GAPDH a
ubiquitously expressed housekeeping gene was used as in-
ternal normalizing control. The 30 μl reactions were car-
ried out at 48°C for 30 minutes, 95°C for 10 minutes,
followed by 40 cycles of 95°C for 15 s and 60°C for 1 mi-
nute in 96-well optical, real-time PCR plates.
Immunofluorescent cytochemical analysis
Cultured human astrocytes were fixed, at experiment-
specific time points, with 1:1 acetone: methanol (V/V)
solution for 20 minutes at −20°C and blocked with block-
ing buffer (2% bovine serum albumin containing 0.1%
Triton X-100) for 1 h. Cells were then incubated with pri-
mary antibodies specific to AEG-1 (1:200) or Ki67 (1:200,
Abcam, Cambridge, MA, USA) or proliferating cell
nuclear antigen (PCNA) (1:200, Cell Signaling Technolo-
gies, Danvers, MA, USA) and GFAP (1:400) in blocking
buffer for 2 h. Cultures were then washed and stained with
Alexa FluorW secondary antibodies, anti-rabbit (488 nm,
green), anti-mouse (488 nm, green) and anti-chicken
(594 nm, red) (1:100). Nuclei were visualized with DAPI
(1:800, Life Technologies). Micrographs were obtained
on an ECLIPSE Ti-4 using the NLS-Elements BR.
3.0 software.
Wound-healing assay
A well established in vitro wound-healing model previ-
ously characterized to study migration of cells in culture
was utilized [32]. Briefly, human astrocytes were plated
at a density of 0.1 × 106 cells per 48-well or 2.0 × 106 cells
per 6-well tissue culture plate, and grown to confluence
for 48 h. The medium was then aspirated and carefully,
a thin stretch of the confluent layer was scratched using
sterile 10 μl pipette tip to induce injury. Fresh astrocyte
medium was added and the wound was allowed to heal.
The wound healing and intracellular localization of
AEG-1 in the migrating cells was evaluated at 8, 24, 36
and 48 h by fixing and performing immunostaining with
anti-AEG-1 and anti-GFAP antibodies as described
above. Live images of migrating cells were obtained
using a phase contrast microscope (Zeiss Invertoscope
40C) (Carl Zeiss Microscopy, LLC, Thornwood, NY,
USA) at 8, 24, 36 and 48 h. For protein analysis follow-
ing wound healing, cells were plated to confluence into
six-well tissue culture plates and injured by three equi-
distant parallel scratches/well, using a sterile 10 μl
pipette tip. To ensure sufficient protein for analysis,
multiple wells were scratched and combined protein
pulled down for cytoplasmic and nuclear analysis.
Confocal analysis
Human astrocytes were grown to confluence in glass
bottom 48-well tissue culture plates (MatTek Corp.,
Ashland, MA, USA) at a density of 0.1 × 106 cells/well
for 48 h. The cells were then scratched, as described
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above, and carefully fixed and stained with antibodies
specific to AEG-1, fibrillarin (1:200, mouse monoclonal,
Abcam), GFAP and DAPI at 48 h post scratch. Micro-
graphs were obtained on an Olympus IX71 Microscope
(Olympus America Inc., Center Valley, PA, USA).
Confocal colocalization analysis and two-dimensional
histogram was performed using BioimageXD soft-
ware (Free Software Foundation Inc., Boston, MA,
USA). A P value >0.95 was accepted as statistically
significant colocalization.
siRNA transfection of astrocytes
Cultured human astrocytes were transfected with ON-
TARGETplusW small interfering RNA (siRNA) specific
to AEG-1 (siAEG-1), scrambled non-targeting siRNA
(siCon, Thermo Scientific, Waltham, MA, USA) and
without siRNA (mock) using the Amaxa™ P3 primary
cell 96-well nucleofector kit (Lonza, Walkersville, MD,
USA) according to the manufacturer’s instructions.
Briefly, 1.6 million astrocytes were suspended in 20 μl
nucleofector solution containing siCon or siAEG-1
(100 nM) and transfected using a Nucleofector/Shuttle
(Lonza) device. Transfected cells were supplemented with
astrocyte media and incubated for 30 minutes at 37°C prior
to plating. After 48 h, cells were washed and used
experimentally.
In vitro cell migration assay
The siRNA-transfected astrocytes were plated in 96 well
Oris™ cell migration assay plates (Platypus Technolo-
gies, Madison, WI, USA) with adherent cell-seeding
stopper at a density of 7.5 × 104 cells/well and incubated
at 37°C for 48 h. Following growth to confluence, the
cell-seeding stopper was removed and cells were washed
with sterile PBS. Live cell imaging of cell migration into
the stopper/wound zone was performed by treating cells
in phenol-free astrocyte media with Hoechst, a nuclear
dye (1:1,000, Life Technologies) at 37°C for 20 minutes
prior to imaging daily for 5 days. Cell migration was
quantified by counting the number of Hoechst positive
cells in the center of the wound at each time point. Sep-
arate images from four replicate wells were assayed from
0 to 120 h and the average numbers of migrated cells
were plotted. According to manufacturer’s instructions,
an OrisTM detection mask was kept intact to ensure the
quantification of cells only in the detection zone (wound
site).
Measurement of cell proliferation
Non-transfected and transfected (mock, siAEG-1 or
siCon) human astrocytes were plated in 48-well tissue
culture plates for 48 h. The cells were fixed and immu-
nostained for Ki67 or PCNA and GFAP as described
above. Positive cells in ten micrographs of different
quadrants in each of three replicate wells were counted.
Western blot analysis
Confluent astrocyte cultures in six-well tissue culture
plates were injured as described above. At 48 h after
injury, cytoplasmic and nuclear protein extracts were
isolated using the NE-PER nuclear and cytoplasmic
extraction kit (Thermo Fisher Scientific). Cytoplasmic
and nuclear protein samples (10 and 20 μg, respectively)
were boiled with 4 ×NuPAGE LDS loading sample
buffer at 100°C for 5 to 10 minutes, resolved by
NuPAGE 4% to 12% Bis-Tris gel and subsequently trans-
ferred to a polyvinyldifluoride (PVDF) membrane using
i-Blot (Life Technologies). The membrane was incubated
with anti-AEG-1 antibody (1:300) overnight at 4°C, washed
and then incubated with anti-rabbit goat antibody IgG con-
jugated to horseradish peroxidase (1:10,000, Bio-Rad,
Hercules, CA, USA) for 2 h at room temperature. The
membrane was then developed with SuperSignal West
Femto substrate (Thermo Fisher Scientific) and imaged in a
Fluorochem HD2 Imager (Proteinsimple, Santa Clara, CA,
USA). β-Actin (1:4,000, Sigma Aldrich, St. Louis, MI, USA),
GAPDH (1:1,000, Santa Cruz Biotechonology, Santa Cruz,
CA, USA) and Lamin A/C (1:3,000, Cell Signaling Techno-
logy) were used as loading controls for cytoplasmic and
nuclear extracts, respectively.
Statistical analyses
Statistical analyses were performed using Prism 5.0
(GraphPad Software, La Jolla, CA, USA), with one-way
analysis of variance (ANOVA) and Newman-Keuls post
test for multiple comparisons. Statistical analyses with a
paired t test were used for comparisons between siCon
and siAEG-1, and between no scratch and scratch. A
two-way ANOVA was used for statistical analyses of
comparison between siCon and siAEG-1 treatments.
Significance was set at P <0.05 and data represents
means ± SEM. Presented data are representative of a
minimum of three independent replicates repeated in
two or more independent donors.
Results
AEG-1 colocalizes with reactive astrocytes in an in vivo
brain injury mouse model
Reactive astrocytes in surgically resected and inflamma-
tory areas of brain show an altered phenotype with
increased proliferation and migration by modulating the
expression and function of significant intracellular mole-
cules [33-35]. Therefore, in the present study we ana-
lyzed AEG-1 expression in astrocytes undergoing
reactive astrogliosis. An in vivo brain injury mouse
model of reactive astrogliosis was used to investigate the
change in AEG-1 astrocyte expression in response to
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injury in an intact healthy CNS. The model circumvents
one of the central caveats for biochemical analyses,
cellular heterogeneity, in large batches of in vitro
primary astrocyte cultures. A stereotactic PBS injection
(5 μl) into the claudate/putamen in the left hemisphere
of a NOD/SCID mouse was compared to the non-
injected contralateral hemisphere (Figure 1A). Immu-
nostaining with GFAP (red, astrocyte marker) antibody
and DAPI identified activated astrocytes comprising a
glial scar tissue around the needle tract, 4 days post
injection. Overall the number of GFAP positive cells
increased, indicating reactive astrogliosis (Figure 1B).
Furthermore, AEG-1 (green) costaining localized to the
perinuclear cytoplasmic region of astrocytes in the non-
injected contralateral hemisphere (inset image, Figure 1C).
However, the number of AEG-1-GFAP double positive
astrocytes (yellow, inset image, Figure 1D) increased
dramatically near the needle tract. Thus, indicating that
brain injury/trauma induces AEG-1 expression in astro-
cytes during reactive astrogliosis.
AEG-1 regulates astrocyte migration and proliferation
For further mechanistic studies involving the quantifica-
tion of the dependency of astrocytes on AEG-1 for or-
chestrating cellular responses to trauma, we performed
in vitro studies following AEG-1 knockdown in human
astrocytes. This model allows direct manipulation of
astrocyte AEG-1 responses and further characterization
of its role during injury and inflammation. In order to
investigate the role of AEG-1 in astrocyte migration,
human astrocytes transfected with siAEG-1 and siCon
were assayed by in vitro Oris™ cell migration assay.
Small interfering RNA specific towards AEG-1 signifi-
cantly reduced AEG-1 mRNA levels at 24 h, which were
sustained through 120 h (P <0.001, Figure 2A), and
reduced 48 h AEG-1 protein levels by approximately
three-fold (P <0.01, Figure 2B) as compared to siCon-
transfected astrocytes. AEG-1 protein knockdown was
sustained though 120 h (data not shown). In the Oris™
cell migration assay, a relatively clear cell-free zone of in-
jury was achieved at the beginning of the assay following
removal of the cell-seeding stopper, in both siAEG-1-
transfected and siCon-transfected astrocytes, which
showed progressive healing by migrating astrocytes over
120 h (representative images, white box, Figure 2C1-C8).
Directional movement of injured astrocytes towards the
wound site was noted over time via injury-directed orienta-
tion of astrocyte nuclei. The wound was completely healed
by 120 h in siCon-transfected astrocytes as compared
to siAEG-1-transfected astrocytes. AEG-1 knockdown
Figure 1 Astrocyte elevated gene-1 (AEG-1) colocalizes with reactive astrocytes during astrogliosis. AEG-1 expression in activated
astrocytes of mouse brain, 4 days post stereotactic phosphate-buffered saline (PBS) injection, was analyzed by immunofluorescent microscopy.
The non-injected contralateral hemisphere was used as a control. Immunostaining for glial fibrillary acidic protein (GFAP) (red, astrocyte marker)
and 4', 6-diamidino-2-phenylindole (DAPI) (blue, nuclear marker) identified the needle tract of activated astrocytes (A,B). Non-injected (inset
image, (C) and PBS-injected contralateral hemispheres costained for AEG-1 and GFAP, were assessed for AEG-1 expression and colocalization with
GFAP (yellow, inset image, (D).
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reduced astrocyte migration into the injury site, which was
significant at 120 h as compared to siCon (P <0.001,
Figure 2D). Thereby indicating that AEG-1 is required for
astrocyte migration and thus may regulate the progression
of wound healing.
The decrease in the number of Hoechst positive cells
at the injury site following AEG-1 knockdown can also
be accounted for by a change in astrocyte proliferation
in addition to astrocyte migration. Therefore, to assess
AEG-1 regulation of astrocyte proliferation, the expres-
sion of cell proliferation markers Ki67 and PCNA was
assayed following AEG-1 knockdown in human astro-
cytes. Immunofluorescent staining for Ki67 (green,
Figure 3A1-D1) or PCNA (green, Figure 3A2-D2) and
GFAP (astrocyte marker, red) decreased in siAEG-1-
transfected astrocytes as compared to controls. Nuclear
Ki67 and PCNA staining was detected consistently in all
controls. The Ki67 (arrow, Figure 3A1,D1) or PCNA
(arrow, Figure 2A,D2) staining intensity as well as the
number of Ki67 or PCNA positive astrocytes signifi-
cantly decreased following AEG-1 knockdown as com-
pared to controls (P <0.001, Figure 3E,F). These data
demonstrate that astrocyte proliferation requires AEG-1.
AEG-1 localizes to the astrocyte nucleolus during
reactive astrogliosis
Next, we sought to identify possible injury-induced
changes in the intracellular localization of AEG-1 in
astrocytes using an in vitro wound-healing model. In this
model, live phase contrast images of the wound showed
complete healing by 48 h (Figure 4A1-F1). Migration of
astrocytes into the wound site from either sides of the
scratch/wound could be detected starting from 24 h. In
response to injury, astrocyte morphology was altered
Figure 2 Astrocyte elevated gene-1 (AEG-1) mediates astrocyte migration during wound healing. Human astrocytes were transfected with
AEG-1 specific siRNA (siAEG-1) or non-targeting, scrambled siRNA (siCon) by nucleofection and plated for 48 h. Messenger RNA was isolated at
24 h and 120 h post recovery and AEG-1 levels were measured by real-time polymerase chain reaction (PCR) (***P <0.001, (A)). In parallel
experiments, immunoblotting was performed for AEG-1 at 48 h; β-actin was used as normalizing loading control (**P <0.001, (B)). Transfected
astrocytes were plated to confluence for 48 h into Oris™ migration assay plates and then injured by removal of the cell-seeding stopper.
Migrating astrocytes were visualized with Hoechst nuclear stain at various time points. Micrographs are shown for siCon-transfected (C1,C3,C5,C7)
and siAEG-1-transfected astrocytes (C2,C4,C6,C8). The number in the lower right corner of the white box (C1-C8) show number of cells in the
area of the injury. Separate images from four replicate wells were analyzed to quantify the number of cells present (***P <0.001, (D)).
Representative data from three individual donors assayed in triplicate is shown.
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with extensive processes protruding from their soma to-
wards the wound site with dense staining for GFAP
(red) and altered AEG-1 (green) intracellular localization
(Figure 4A2-E2). Injury-induced activation of astrocytes
was observed clearly in GFAP micrographs at 24 h
(Additional file 1). Interestingly, AEG-1 was also detected
in areas within the migrating astrocyte nucleus, which
showed an increase in intensity in a time-dependent man-
ner. Upon complete wound healing (48 h), AEG-1 clearly
localized to nuclear pockets of migrated astrocytes
(Figure 4G). These five to six dense AEG-1 positive areas
in the nucleus of injured astrocytes differed signifi-
cantly from the cytoplasmic and nuclear localization in
non-wounded astrocyte cultures where AEG-1 appears
more prominent in the perinuclear region, less so in the
nucleoplasm, and is diffuse throughout the cytoplasm
(Additional file 2). The injury-induced changes in AEG-1
intracellular localization were quantified by immunoblot-
ting cytoplasmic and nuclear extracts of injured astrocytes
for AEG-1 (Figure 4H). Injury induced higher cytoplasmic
AEG-1 levels and significantly reduced nuclear AEG-1
levels as compared to non-injured astrocytes (Figure 4I,J).
However, immunoblotting of astrocyte whole cell lysates,
48 h after injuries of increasing severity, did not indicate
changes in AEG-1 protein levels (Additional file 3). The
interesting observation of subnuclear AEG-1 being detected
in injured astrocytes hinted towards nucleolar localization
and initial immunocytochemical studies showed AEG-1
colocalization with nucleolin within the nuclei of astrocytes
during wound healing (Additional file 4). The injury-
induced specific subnuclear compartmentalization of AEG-
1 in astrocytes was thus assayed by immunostaining for
fibrillarin (nucleolar marker, red, Figure 5A) and AEG-1
(green, Figure 5B). Analysis revealed significant colocaliza-
tion between fibrillarin and AEG-1 (P=1.0; Figure 5C-F),
signifying movement of AEG-1 to the nucleolus during
wound healing.
Discussion
The present work identifies AEG-1 as a novel modulator
of astrocyte injury responses by regulating astrocyte
migration and proliferation. Our in vivo brain injury
mouse model and in vitro cell migration assays provides
evidence for the induction of AEG-1 expression during
gliosis in injured astrocytes and a subsequent alteration
in subcellular distribution consequent to injury. We also
report the nucleolar localization of AEG-1 during astro-
cyte wound healing, which provides direction for future
mechanistic studies.
Figure 3 Astrocyte proliferation requires astrocyte elevated gene-1 (AEG-1). Astrocytes transfected with AEG-1 specific siRNA (siAEG-1) or
non-targeting, scrambled siRNA (siCon) were immunostained with Ki67 or proliferating cell nuclear antigen (PCNA) (green, proliferation marker)
and glial fibrillary acidic protein (GFAP) (red, astrocyte marker) antibodies. Untransfected and mock-transfected astrocytes were stained in parallel.
Micrographs at 20 × original magnification of Ki67 or PCNA with GFAP costaining for non-transfected control (A1,A2), mock-transfected (B1,B2),
siCon-transfected (C1,C2) and siAEG-1-transfected astrocytes (D1,D2) are shown. (E) This panel shows the number of Ki67 positive cells in ten
micrographs from replicate wells for each condition (***P <0.001). (F) This panel shows the number of PCNA positive cells in ten micrographs
from replicate wells for each condition (***P <0.001). All micrographs are 20 × original magnification, unless otherwise noted. Immunostaining
data is representative of three individual donors assayed in triplicate.
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Reactive astrogliosis, a prerequisite for CNS wound hea-
ling, orchestrates events that lead to glial scar formation,
which is critical for maintaining CNS homeostasis [36].
While AEG-1 was first described as an HIV-1-inducible
transcript in astrocytes [1], this is the first report that
describes a critical role of AEG-1 in reactive astrogliosis,
the first line of defense for any CNS injury [23]. The in vivo
brain injury mouse model provides evidence for the induc-
tion of AEG-1 expression during gliosis, however, AEG-1
levels in injured astrocytes remained unchanged in the
in vitro wound-healing model. This distinction may be due
to the difference in the complexities of the two models. In
the intact CNS brain injury model there are elevated levels
of AEG-1-inducing agents, such as TNFα and interleukin
1β (IL-1β), secreted by other non-neural cells such as acti-
vated microglia [37], in contrast to the confluent layer of
pure astrocyte cultures of the in vitro wound-healing
model. AEG-1 induction at the wound site in the in vivo
brain injury mouse model colocalized with reactive astro-
cytes, indicating a possible involvement of AEG-1 in the in-
jury responses of astrocytes.
During gliosis, astrocytes undergo multitude of changes
in their gene expression patterns, secretion profiles and
morphological traits that lead to a reactive phenotype
capable of mediating wound healing [17,38,39]. AEG-1 in-
duction following injury can alter many intracellular sig-
naling pathways, such as nuclear factor (NF)κB [8,10],
Wnt [40], cyclic adenosine monophosphate [5,41], mito-
gen activated protein kinases (MAPK) [40] and phosphati-
dylinositol 3-kinases-AKT [42]. It is interesting to note
that AEG-1 expression in astrogliomas has been shown to
induce CXCL8 expression [8] and matrix metalloprotei-
nase-9 production [5], both of which show a dramatic in-
crease during gliosis [43,44]. Reactive astrogliosis is often
associated with deregulated glutamate clearance, which is
responsible for toxicity to neurons [45,46]. Interestingly,
AEG-1 has been shown to suppress the expression of exci-
tatory amino acid transporter-2 in astrogliomas [47-49].
Besides the altered secretory profiles of reactive astrocytes,
structural changes such as elevated expression of GFAP,
vimentin and nestin are observed during reactive astroglio-
sis [50]. These can also be modulated by AEG-1, by
Figure 4 Astrocyte elevated gene-1 (AEG-1) localizes to nuclear pockets during wound healing in cultured human astrocytes. Confluent
astrocyte cultures were scratched to mimic injury and subsequent wound healing by migrating astrocytes was monitored for up to 48 h.
Phase-contrast images of the wound tract are shown from 0 to 48 h (A1-F1). In parallel, starting from 8 h post injury, cells were periodically fixed
and immunostained with glial fibrillary acidic protein (GFAP) (red, astrocyte marker) and AEG-1 (green) antibodies (A2-E2). Higher resolution
micrograph of AEG-1 and GFAP costaining in migrated astrocytes is shown (40 ×, (G)). All images are 20 × original magnification, unless otherwise
noted. Cytoplasmic and nuclear protein extracts of astrocytes following wound healing were immunoblotted for AEG-1 (H); cytoplasmic
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and nuclear lamin A/C were used as subcellular fraction normalizing controls (*P <0.01, (J)).
Representative data from three individual donors assayed in triplicate. Immunoblotting data is representative of three individual donors.
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functioning as a coactivator for signaling molecules, such as
NFκB and MAPK. AEG-1 has been reported to physically
interact with NFκB p65 subunit and activate NFκB respon-
sive genes, most of which are overexpressed during glio-
sis [10,51].
Recruitment of astrocytes to the site of injury is an im-
portant primary step for initiation of reactive astrogliosis
[36]. Here, we report for the first time AEG-1-mediated
regulation of human astrocyte migration. As a metastasis
adhesion protein, increased cytoplasmic AEG-1 expression
has been shown to promote augmented migration, invasion
and metastasis of cancer cells such as neuroblastoma and
malignant gliomas, facilitating anchorage-independent
growth and survival in the secondary site [1,52]. The
in vitro wound-healing assay utilized in this study allows
characterization of the innate injury-induced subcellular
changes in AEG-1 localization excluding the confounding
factors present in an intact CNS. Here, we report higher
cytoplasmic AEG-1 levels and significantly reduced nuclear
levels following injury, which is similar to AEG-1
localization in highly invasive cancer cells [9]. While AEG-1
has been shown to mediate metastasis as an adhesion pro-
tein, the interacting counterpart on other cells has yet to be
identified and further mechanistic studies are lacking [53].
Figure 5 Astrocyte elevated gene-1 (AEG-1) localizes to the astrocyte nucleolus during wound healing. At 48 h post injury astrocytes
were immunostained for fibrillarin (red, nucleolar marker, (A)), AEG-1 (green, (B)) and 4', 6-diamidino-2-phenylindole (DAPI) (blue, nuclear marker,
(C)) and micrographed by confocal microscopy. Z-stack micrographs of fibrillarin fluorescence were overlaid upon AEG-1 and DAPI (D). Higher
magnification micrograph of AEG-1 and fibrillarin costaining is shown (E). A scatter plot of overlapping AEG-1 and fibrillarin pixels was generated
(P= 1, (F)). Representative confocal images are 200 × original magnification from 2 individual donors assayed in triplicate.
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However, AEG-1 was previously reported to induce matrix
metalloproteinase production in glioma cells, thereby facili-
tating glioma invasion [5]. A study in breast cancer revealed
that AEG-1 promotes epithelial-mesenchymal transition
and enhanced migration by upregulating mesenchymal
markers, downregulating epithelial markers, and inducing
nuclear accumulation of NFκB [5,54]. It has been
reported that ectopic expression of AEG-1 could aug-
ment anchorage-independent growth of non-tumorigenic
melanocytes and immortalized astrocytes [42], whereas
AEG-1 knockdown reduced cell viability and promoted
apoptosis in prostate cancer cells [55].
Our study demonstrated reduced astrocyte migration fol-
lowing AEG-1 knockdown. The decrease in migratory cap-
acities was sustained over 5 days indicating that AEG-1
may also have influenced astrocyte proliferation. Astrocytic
hyperproliferation is yet another hallmark of reactive astro-
gliosis [27]. AEG-1 knockdown also reduced astrocyte
proliferation as assayed by change in Ki67 and PCNA
expression. Nuclear protein Ki67 is expressed in all cell
cycle phases except G0, whereas nuclear protein PCNA
levels are highest during the G1/S phase of the cell cycle
[56]. Therefore, the decrease in both Ki67 and PCNA posi-
tive astrocytes following AEG-1 knockdown reported here
implies G1/S phase cell cycle arrest following AEG-1
knockdown, indicating a plausible role of AEG-1 during
these cell cycle phases, and further studies are warranted. It
remains to be seen whether overexpression of AEG-1 will
enhance the ability of astrocytes to participate in gliosis.
Although, a number of AEG-1-interacting proteins have
been identified [10,11,13], a complete understanding of
the biological functions and biochemical characteristics,
particularly the molecular triggers for differential sub-
cellular localization and its subsequent effects on cellular
mechanisms remains elusive to date. AEG-1 localization
to the nucleolus has been reported in a few isolated cancer
types, but is most frequently detected either in the nucleo-
plasm or cytoplasm of many metastatic tumors [9,57].
Here, we report injury-induced colocalization of AEG-1
with nucleolar protein fibrillarin, a component of the
small nuclear ribonucleoprotein complex that is required
for processing of the pre-rRNA molecules [58,59]. This
suggests a novel role of AEG-1 in pre-rRNA processing
and assembly. Aberrant ribosome biogenesis leads to p53-
dependent G1 arrest, and therefore is crucial for cell sur-
vival and proliferation [60-62]. Recently, cytoplasmic
AEG-1 has been identified as a RNA-binding protein,
which provides survival advantage to cancer cells under
conditions of stress by blocking Rad51 nuclear accumula-
tion [12,63]. Furthermore, AEG-1 has been shown to
Figure 6 Role of astrocyte elevated gene-1 (AEG-1) in reactive astrogliosis. Central nervous system (CNS) insults ranging from mild cellular
disturbances to severe tissue damage and cell death lead to release of molecular mediators of reactive astrogliosis such as inflammatory
cytokines interleukin 1β (IL-1β), tumor necrosis factor α (TNFα) and molecules of oxidative stress such as reactive oxygen species (ROS). These
mediators in turn activate the local healthy astrocyte population by inducing a spectrum of changes in the microenvironment and intracellular
signaling pathways resulting into reactive astrogliosis. Injury triggers increased AEG-1 localization to the cytoplasmic regions and the dense
fibrillar nuclear regions of the astrocyte. This change in intracellular localization of AEG-1 in astrocytes undergoing reactive astrogliosis is a
plausible mechanism of AEG-1-mediated regulation of astrocyte proliferation and migration during reactive astrogliosis.
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physically interact with Staphylococcal nuclease domain-
containing protein 1, a component of the RNA-induced
silencing complex assembly, and to regulate microRNA
processing and function in hepatocellular carcinoma [12].
However, proteomic studies failed to identify a DNA-
binding domain on the AEG-1 protein. Together these
findings imply a potential role as a scaffolding protein of
the small nuclear ribonucleoprotein complex mediating
either transcription and/or processing of the pre-rRNA
molecules. The role of AEG-1 in the nucleolus has not
been investigated to date in either cancer or non-
cancerous cells. Therefore, the current finding of AEG-1
colocalization with fibrillarin provides a physiological basis
for future studies. Additional studies into the physical
interaction between AEG-1 and nucleolar-processing
complex components and mechanism of participation in
pre-rRNA processing are necessary to determine the role
of AEG-1 in astrocytic wound-healing responses.
Restricted HIV-1 infection of astrocytes contributes to
HIV-1-associated neuropathies via multiple mechanisms,
including reactive astrogliosis and glutamate excitotoxicity
[64]. In conjunction to the previous findings on AEG-1, as
a mediator of glutamate excitotoxicity, this study identifies
yet another mechanism of AEG-1-mediated regulation of
HIV-1-associated neuropathies, via regulation of reactive
astrogliosis. In addition, we have previously reported that
disruption of astroglial-neuronal interactions and secre-
tion of neurotoxic cytokines and chemokines during
astrogliosis can also contribute towards neuronal cell atro-
phy [65]. Yet another important molecular change during
reactive astrogliosis is the increase production of reactive
oxygen species such as nitric oxide, nitric oxide synthase,
super oxide dismutase and glotathione [61-63]. Interest-
ingly, previous studies on AEG-1 in glioma have revealed
AEG-1-mediated protection against glocuse deprivation-
induced cytotoxicity [49,64]. Also, AEG-1 increased the
chemotherapeutic resistance of breast cancer cells by
increasing the expression ot multidrug resistance gene 1,
thereby increasing the efflux of toxic waste from the cells
[53,65,66]. Hence, further studies on AEG-1-induced
alterations in the astrocyte secretary profiles are currently
ongoing.
The oncogenic Ha-Ras pathway has been implicated to
induce AEG-1 expression in cancers [66]; however, the
pathway involved in the induction of AEG-1 in normal
non-cancerous cells such as astrocytes has yet to be
investigated. We are currently investigating many of the
molecular triggers and modulators of reactive astroglio-
sis as plausible inducers of AEG-1 in human astrocytes,
including cytokines and growth factors, ischemia-
associated mediators like hypoxia [67], glucose-privation,
and mediators of innate immunity such as LPS [68] and
other toll-like receptor agonists. Thus, additional works
to elucidate the molecular pathways involved in AEG-1
induction in human astrocytes during reactive astroglio-
sis are warranted.
Conclusions
The present work identifies AEG-1 as a novel modulator
of astrocyte injury responses by regulating astrocyte mi-
gration and proliferation. CNS insults of varying severities
induce molecular mediators of reactive astrogliosis, which
trigger induction and/or subcellular compartmentalization
of AEG-1 protein in activated astrocytes to mediate
enhanced migration and proliferation; thereby engender-
ing the preliminary astrocytic responses to injury (Fig-
ure 6). The present finding of the potential function of
AEG-1 in modulating the response of normal astrocytes
surrounding injury site, can impact diverse outcomes in
cancers, neuroinflammation and neurodegenerative dis-
eases by determining the potential for tumor recurrence,
healing of injuries as well as recovery from degenera-
tive processes. Thus, the characterization of the involve-
ment of AEG-1 during reactive astrogliosis has opened
multiple avenues of investigations in neuropathology fo-
cused on the impact of surrounding astrocytes in regu-
lating the response to disease progression as well as
conventional therapeutic interventions.
Additional files
Additional file 1: In vitro wound-healing model induces reactive
astrocytes at the wound site. Confluent astrocyte cultures scratched to
mimic injury were immunostained for glial fibrillary acidic protein (GFAP)
to assay subsequent wound healing. At 24 h post injury, astrocytes near
the wound site show dense GFAP staining with extensive protrusions
arising from the stoma (white arrow) as against the relatively flat
morphology of non-motile astrocytes away from the injury site (yellow
arrow). Representative micrograph, 10 × original magnification, from three
individual donors assayed in triplicate.
Additional file 2: Astrocyte elevated gene-1 (AEG-1) localizes to the
cytoplasm and nucleus in cultured human astrocytes under
unstressed conditions. Human astrocytes were plated for 24 h in 48
well tissue culture plates at a density of 0.1 × 106 cells/well. At 24 h post
plating, cells were immunostained for AEG-1 (green, (A)), glial fibrillary
acidic protein (GFAP) (red, astrocyte marker, (B)) and 4', 6-diamidino-2-
phenylindole (DAPI) (blue, nuclear marker, (C)) and 20 × original
magnification micrographs were overlaid (D). Cytoplasmic (50 μg/lane)
and nuclear (20 μg protein/lane) protein extracts from astrocyte cultures
were immunoblotted for AEG-1 (E). Representative data from three
individual donors.
Additional file 3: Astrocyte elevated gene-1 (AEG-1) protein levels
remained unchanged following in vitro injury to human astrocytes.
Human astrocytes were plated to confluence in six-well tissue culture
plates and scratched to mimic injury using 10 μl pipette tips with
increasing number of scratches (0, 1, 2, 3, 4, and 6). At 48 h post injury,
whole cell lysates were immunoblotted for AEG-1 (A). β-Actin was used
as normalizing control and normalized AEG-1 levels were plotted
following band analysis (B). Representative data from two individual
donors.
Additional file 4: Astrocyte elevated gene-1 (AEG-1) colocalizes
with nucleolar protein nucleolin. At 48 h post injury astrocytes were
immunostained for AEG-1 (green, (A)), nucleolin (red, nucleolar marker,
1:200, Abcam, (B)) and 4', 6-diamidino-2-phenylindole (DAPI) (blue,
nuclear marker, (C)) and 20 × original magnification micrographs were
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overlaid (yellow, inset, (D)). Representative data from two individual
donors assayed in triplicate.
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